Hepatic iron accumulation is reduced in the cholestatic Mdr2-/- mouse

Amy L Sobbe1,2, Kim Bridle1,2, Lesley-Anne Jaskowski1,2

  • 1Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia.

Bioscience Reports
|July 10, 2026
PubMed

Insights

The Mdr2-/- mouse model shows abnormal iron regulation in cholestatic liver disease. Despite reduced hepcidin, these mice exhibit impaired iron uptake, leading to lower liver iron stores.

Area of Science:

  • Hepatology
  • Iron Metabolism
  • Cholestasis Research

Background:

  • The multidrug-resistance 2 knockout (Mdr2-/-) mouse models biliary liver injury, resembling human progressive familial intrahepatic cholestasis type 3.
  • Cholestasis-induced bile acid accumulation is linked to decreased hepcidin, suggesting a connection between liver disease and iron homeostasis.

Purpose of the Study:

  • To investigate iron homeostasis in the Mdr2-/- mouse model of cholestasis.
  • To analyze iron levels and the expression of iron-related genes in Mdr2-/- mice.

Main Methods:

  • Real-time PCR and western blotting were used to analyze iron levels and gene expression.
  • Wild-type and Mdr2-/- mice were fed either an iron-deficient or a carbonyl iron diet to assess iron accumulation and hepcidin response.

Main Results:

  • Mdr2-/- mice on a control diet had reduced hepatic iron stores despite lower hepcidin expression and higher transferrin receptor 1 expression.
  • Mice fed a carbonyl iron diet were resistant to hepatic iron accumulation, indicating impaired hepatocyte iron uptake.

Conclusions:

  • Mdr2-/- mice exhibit abnormal hepatic iron homeostasis, likely due to cholestasis.
  • Impaired hepatic iron uptake may explain the lower liver iron content observed in cholestatic conditions compared to hepatocellular diseases.

Related Concept Videos